Kymera Therapeutics, Inc.
KYMR
Rank in Stocks
#2247
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Share Price
$108.61
Last synced: 2026-10-19
Market Cap
$8.93B
Change (1 day)
3.65%
Change (1 year)
79.51%
Country
US
Trade Kymera Therapeutics, Inc. (KYMR)
Category
Healthcare
Earnings for Kymera Therapeutics, Inc. (KYMR)
Earnings in Jun 2026 TTM: $-299.87M
According to Kymera Therapeutics, Inc. latest financial reports the company's current earnings are $-299.87M. In 2023 the company made an earning of $-146.96M, an increase over its 2022 earnings that were of $-154.81M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Kymera Therapeutics, Inc. from 2018 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-299.87M | 33.96% |
| 2024 | $-223.86M | 52.32% |
| 2023 | $-146.96M | -5.07% |
| 2022 | $-154.81M | 54.47% |
| 2021 | $-100.22M | 119.81% |
| 2020 | $-45.59M | 10.54% |
| 2019 | $-41.25M | 92.14% |
| 2018 | $-21.47M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -1,859.04% |
US
|
|
| $-3.09B | 929.44% |
US
|
|
| $-4.02B | 1,239.30% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -750.49% |
NL
|
